Piper Jaffray Cuts Price Target on Nxstage Medical (NXTM) Following Mixed 4Q Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
NxStage Reports Record Fourth Quarter and Full-Year 2015 Revenue
February 10, 2016 8:04 AM ESTLAWRENCE, Mass., Feb. 10, 2016 /PRNewswire/ -- Â
Highlights:
Full-Year Revenue Increases to $336 million, up 11% from 2014 Full-Year Home Revenue Increases to $183 million, up 16% from 2014 Full-Year Operating Income from Products Business Increases to $9 million Company Highlights Significant Product Introductions for the Next Three Years For Third Consecutive Year, Company Targets 15% Annual Home Revenue GrowthNxStage Medical, Inc. (Nasdaq: NXTM), a leading medical technology company focused on advancing renal care, today reported record revenue for the fourth quarter and fiscal year ended... More
